Introduction
More than five decades ago it was discovered that systemic glutamate injections can destroy retinal tissue in the inner layers (Lucas and Newhouse, 1957) , providing the first evidence for the toxic effects of glutamate. This ''excitotoxicity,'' a term coined by John Olney over a decade later, is now known to occur throughout the brain (Olney, 1969) , is dependent on calcium influx (Choi, 1987) through N-methyl-D-aspartate (NMDA) ionotropic glutamate receptors (Choi et al., 1988) , and is implicated in a variety of neurological conditions (Dong et al., 2009) . Unfortunately, treating disorders of the nervous system with general NMDA receptor (NMDAR) blockers is associated with unacceptable side effects, largely owing to the paradoxical involvement of NMDAR signaling in both cell death as well as cell survival and plasticity (Hardingham and Bading, 2003) ; therefore, early clinical trials for NMDAR antagonists have been disappointing. However, a more recent ''localization hypothesis'' of NMDARs offers new promise in differentiating these dramatically different downstream effects of NMDAR activation. In its simplest form, this hypothesis suggests that the activation of synaptic NMDARs promotes cell survival, while activation of those outside of the synapse (extrasynaptic) promotes cell death signaling (Hardingham et al., 2002) . With some notable recent exceptions (Papouin et al., 2012; Wroge et al., 2012; Zhou et al., 2013b) , the localization hypothesis has been supported by numerous studies and is further substantiated by the observation of elevated extrasynaptic NMDAR expression and/or activation in disease states. In this Review, we will briefly discuss evidence for (as well as against) the NMDAR localization hypothesis. Key signaling pathways involved in this dichotomous NMDAR function will be highlighted as well as their respective roles in synaptic plasticity. While much of this literature has been excellently reviewed elsewhere (Hardingham and Bading, 2010) , we will then focus primarily on the contribution of extrasynaptic NMDARs to chronic neurodegenerative disease and acute neurological insults.
Extrasynaptic NMDARs: Signaling Pathways and Synaptic Plasticity Downstream Signaling from Synaptic and Extrasynaptic NMDARs If synaptic and extrasynaptic NMDARs play different roles in cell survival and cell death, it follows that these two receptor populations must trigger different effects inside the cell subsequent to their activation. This idea has received tremendous support by studies that selectively activate synaptic or extrasynaptic NMDARs; the former generally being achieved through pharmacological (4-aminopyridine [4-AP] to block K + channels, and/or bicuculline to block GABAergic inhibition) or electrical enhancement of synaptic activity and the latter by synaptic NMDAR preblock with MK-801 followed by exogenous NMDA application ( Figure 1A ). Memantine, a noncompetitive, moderate affinity NMDAR antagonist with fast on/off kinetics, has also been used to assess the contribution of extrasynaptic NMDAR activity to cell signaling and death, as it has been shown to preferentially block tonically activated extrasynaptic NMDARs rather than phasically activated synaptic NMDARs (Xia et al., 2010) . Using the above methodology, it has been shown that selective synaptic NMDAR stimulation increases extracellular signal-regulated kinase 1/2 (ERK1/2) activation, cAMP response element-binding protein (CREB) phosphorylation and brain-derived neurotrophic factor (BDNF) expression, enhances antioxidant defense, and provides neuroprotection, whereas extrasynaptic NMDAR stimulation does the opposite (Hardingham et al., 2002; Hardingham and Bading, 2010; Figure 1B) . Nuclear calcium, an important regulator of gene expression, plays a key role in the prosurvival effects of synaptic stimulation and is disrupted by extrasynaptic NMDAR activity (reviewed in Bading, 2013) . Furthermore, distinct isoforms of calcium-dependent proteases called calpains are differentially activated by synaptic and extrasynaptic NMDAR stimulation, with the former activating m-calpain and the latter activating m-calpain. Interestingly, m-calpain, but not m-calpain, was shown to result in proteolysis of striatal-enriched protein phosphatase (STEP), with subsequent activation of p38 mitogen-activated protein kinase (p38MAPK) and cell death Xu et al., 2009) , providing further support for the deleterious nature of extrasynaptic NMDAR activity. Any shift in balance to reduce synaptic or enhance extrasynaptic NMDAR signaling may be detrimental to neuronal health. How can NMDAR activation at the cell surface act in the nucleus to influence gene expression in a manner that reflects the precise membrane localization at which the signal originates? A new study (Karpova et al., 2013) sheds some light on this mystery by demonstrating a synaptic NMDAR-driven, ERK1/2-dependent phosphorylation of a protein known as Jacob. Specific synaptic NMDAR stimulation results in Jacob phosphorylation by ERK1/2 and long-distance transport of phosphorylated Jacob to the nucleus. Conversely, extrasynaptic NMDAR stimulation fails to phosphorylate Jacob yet still induces nuclear translocation, resulting in synaptic-and extrasynapticinduced translocation of phosphorylated and nonphosphorylated Jacob to the cell nucleus, respectively. In support of the NMDAR localization hypothesis, when in the nucleus, phosphorylated Jacob is associated with elevated phospho-CREB (p-CREB), BDNF, and Arc3.1 levels, while nonphosphorylated Jacob is associated with reduced p-CREB, dendritic complexity, and synaptic connectivity (Dieterich et al., 2008; Karpova et al., 2013) . As ERK1/2 is known to be activated and inactivated by synaptic and extrasynaptic NMDARs, respectively (Ivanov et al., 2006) , ERK1/2 and subsequent Jacob phosphorylation appears to play a major role in communicating the origin of NMDAR activity to the nucleus. A list of some of the intracellular factors that are differentially influenced by location-based NMDAR signaling is shown in Figure 1 and is reviewed in greater detail in Hardingham and Bading (2010) .
Synaptic and Extrasynaptic NMDARs: Role in Synaptic Plasticity
Synaptic plasticity permits the regulated strengthening or weakening of specific connections in an organized fashion and is well accepted to represent the neurological underpinnings of learning and memory. The reliance on NMDARs of various forms of longterm potentiation (LTP) and long-term depression (LTD) has been long established and recent evidence implicates differential roles for synaptic and extrasynaptic NMDARs in synaptic plasticity. Conditions that increase the extrasynaptic glutamate concentration, including increased stimulation intensities, knockout or inhibition of the glial glutamate transporter, or exogenous applications of NMDA, can all impair LTP (Izumi et al., 2008; Katagiri et al., 2001; Li et al., 2011) . This inhibition of LTP can be reversed by NMDAR antagonists, suggesting that extrasynaptic NMDARs can obstruct activity-dependent plasticity. Intriguingly, when synaptic receptors are preblocked with MK-801, a theta-burst simulation protocol that normally generates a potentiating effect can instead produce LTD, suggesting that selective activation of extrasynaptic NMDARs induces LTD (Liu et al., 2013) . In a recent study by Papouin and colleagues, specific enzymes targeting the degradation of either D-serine or glycine were used to show that D-serine and glycine act specifically as endogenous coagonists at synaptic and extrasynaptic NMDARs, respectively (Papouin et al., 2012 ; but see Rosenberg et al., 2013 and below) . The authors took advantage of this discrimination and used D-serine degradation to isolate extrasynaptic NMDARs and glycine degradation to isolate synaptic NMDARs to study the contribution of each receptor population to Hebbian forms of plasticity. When D-serine was degraded, thereby inhibiting synaptic NMDARs, the magnitude of LTP expression was attenuated, suggesting a key role for synaptic NMDARs in LTP. On the other hand, degradation of glycine had no effect on LTP, suggesting that extrasynaptic NMDAR activity is not required for LTP induction. In contrast, both synaptic and extrasynaptic NMDARs are required for full LTD (B) Using similar methodology, it has been shown that stimulation of synaptic NMDARs activates prosurvival and inhibits prodeath intracellular signaling, whereas extrasynaptic NMDAR activation does the opposite. Black and red text denotes an increase and decrease, respectively, in the activation, expression, or function of a particular intracellular signal after selective NMDAR stimulation. For greater detail, see Hardingham and Bading (2010) . See text for references.
expression, although the LTD deficit is more pronounced when extrasynaptic NMDARs are inhibited by glycine degradation (Papouin et al., 2012) . Location, Location . Subunit Composition NMDARs assemble as heterotetramers with two obligatory GluN1 subunits in combination with two additional GluN2 (GluN2A-GluN2D) and/or GluN3 (GluN3A-GluN3B) subunits, resulting in a heterogeneous population of NMDARs with diverse pharmacological properties, kinetics, and downstream signaling pathways (Cull-Candy et al., 2001; Paoletti et al., 2013; Paoletti and Neyton, 2007; Sanz-Clemente et al., 2013) . The large majority of NMDARs in the CNS assemble as diheteromers of GluN1/ GluN2A or GluN1/GluN2B, or as a triheteromer of GluN1/ GluN2A/GluN2B. Subunit expression is developmentally regulated, with GluN2B-containing NMDARs dominating early in development and GluN2A-containing NMDARs dominating in adulthood.
A controversial theory postulates dramatic localization differences between GluN2A-and GluN2B-containing receptors, in that the former is found within, and the latter outside, the synapse. While it is clear that the partition is not absoluteGluN2B can be found synaptically and vice versa (Harris and Pettit, 2007; Liu et al., 2004; Petralia et al., 2010; Thomas et al., 2006 )-a GluN2A/synaptic and GluN2B/extrasynaptic bias has received a fair amount of support over the years (Groc et al., 2006; Martel et al., 2009; Sanz-Clemente et al., 2013; Tovar and Westbrook, 1999) . Interestingly, GluN2A-type NMDARs generally have a greater association with cell survival, whereas GluN2B-type NMDARs are linked to cell death signaling (Lai et al., 2011) ; therefore, a ''subunit hypothesis'' can work in tandem with the ''localization hypothesis'' to form a ''unified hypothesis'' (Lai et al., 2011) in that extrasynaptic GluN2B-containing NMDARs may preferentially signal to cell death after activation in comparison to synaptic GluN2A activation. A recent elegant study, using chimeric constructs of GluN2 subunits and a knockin mouse model in which the C-terminal tail of GluN2A was swapped for that of GluN2B, provided convincing evidence that intracellular signaling via the GluN2B C terminus is a large contributor to NMDA-induced toxicity .
A unified hypothesis that associates GluN2B/extrasynaptic and GluN2A/synaptic NMDARs with cell death and survival, respectively, is indeed an attractive one in its simplicity and is supported by numerous studies. However, before proceeding to a discussion regarding the role of NMDAR location in disease, it must be noted that recent findings have suggested a significant role for GluN2A and synaptic NMDARs in excitotoxic cell death under certain experimental conditions (Papouin et al., 2012; Wroge et al., 2012; Zhou et al., 2013a Zhou et al., , 2013b , and perhaps it should not be surprising that a universal rule of NMDAR toxicity has yet to be agreed upon. Between-study comparisons are made difficult by the variety of experimental approaches (e.g., including analysis of necrotic versus apoptotic cell death), the use of a wide range of neurodevelopmental stages, the lack of pharmacological means to definitively distinguish NMDAR subtypes, and a general disregard for the existence of GluN1/GluN2A/GluN2B triheteromers, which have been recently estimated to account for as much as two-thirds of synaptic NMDAR currents (Tovar et al., 2013) . Specifically, although there are inhibitors such as ifenprodil and Ro 25-6981 that show high selectivity for GluN2B-containing NMDARs, pharmacological agents specific for GluN1/GluN2A diheteromers or GluN1/GluN2A/GluN2B triheteromers are not well developed. Even within the obligatory GluN1 subunit, there are eight different isoforms which show region-specific expression patterns and can alter NMDAR pharmacological and trafficking properties (Paoletti et al., 2013) . With regards to developmental stage, it is estimated that in cultured neurons, as many as 90% of the NMDARs are extrasynaptic after 1 week in vitro, whereas this number is reduced to 50% or less by 2 weeks (reviewed in Gladding and Raymond, 2011) , making it difficult to draw conclusions regarding the contribution of synaptic receptors to cell survival or death from studies using immature culture systems. Furthermore, as extrasynaptic NMDARs are more likely to receive tonic activation than the phasic activity patterns generally seen at synaptic receptors, differences in downstream signaling may depend in part on the tonic or phasic nature of NMDAR stimulation. Lastly, recent evidence opposing the localization hypothesis relied heavily on the selectivity of D-serine for synaptic and glycine for extrasynaptic NMDARs as a means to isolate NMDARs based on their location (Papouin et al., 2012) . However, this interpretation is complicated by the demonstration that both glycine and D-serine can be released through neuronal Asc-1 transporters and act as synaptic NMDAR coagonists (Rosenberg et al., 2013) . While it is true that acute D-serine degradation dramatically reduces synaptic NMDAR-mediated current, and that such a treatment offers significant neuroprotection (Mothet et al., 2000; Papouin et al., 2012; Shleper et al., 2005) , it has been suggested that the possibility of D-serine also acting as a coagonist at extrasynaptic sites has not been definitively ruled out (Gray and Nicoll, 2012) .
From the conflicting data it is suggested that some hierarchy of NMDAR excitotoxicity exists in which developmental stage, NMDAR subunit composition, type (tonic/phasic) and duration of activation, as well as NMDAR localization can all play a role. In this Review, we will focus on the localization aspect of this hierarchy and discuss the contribution of extrasynaptic NMDARs to cell death in diseases of the nervous system.
Extrasynaptic NMDARs and Diseases of the Nervous System
The pathogenesis of more and more CNS disorders is being attributed, at least in part, to extrasynaptic NMDAR activity. Some notable examples include the neurodegenerative Alzheimer disease (AD) and Huntington disease (HD), as well as ischemia/hypoxia, traumatic brain injury (TBI), and epilepsy. Enhanced glutamatergic activity at extrasynaptic sites can occur in numerous ways, including a failure of glutamate uptake, gliotransmission, reverse operation of the glutamate transporters, an increase in presynaptic glutamate release probability, aberrant burst firing of presynaptic inputs, or an increase in the number and/or stability of NMDARs at extrasynaptic sites. Many of these disorders also share common signaling pathways downstream of extrasynaptic NMDAR activity that contribute to neurotoxicity. Therefore, understanding the neurobiology underlying enhanced extrasynaptic NMDAR activation and subsequent downstream signaling in CNS disorders can aid in developing treatment strategies for neurologic disease.
Alzheimer Disease
Evidence for an Extrasynaptic NMDAR Involvement in AD. AD is the most common form of dementia and the most common neurodegenerative disease. It is estimated that over five million Americans have AD. This number has risen by over 60% in the last decade and is expected to more than double by 2050 (Alzheimer's Association, 2012); such prevalence rates have ignited considerable interest in the neurobiology of AD. Overwhelming evidence supports the idea that soluble oligomers of the amyloid-beta protein (Ab) and hyperphosphorylation of tau protein represent the major toxic species underlying the synapse loss, plasticity and cognitive deficits, and eventual neurodegeneration associated with AD (Danysz and Parsons, 2012; Gong and Iqbal, 2008) . Of interest to the present Review is that recent investigation into the neurotoxic effects of oligomeric Ab and phosphorylated tau has identified a critical involvement of NMDARs and, in particular, extrasynaptic NMDARs.
Ab negatively regulates the number of NMDARs at postsynaptic sites, thereby disrupting the balance between synaptic and extrasynaptic NMDAR activity. When applied to cultured cortical neurons, Ab enhances NMDAR endocytosis and decreases synaptic expression (Snyder et al., 2005) , consistent with the finding that calcium influx through NMDARs after glutamate uncaging at single spines is significantly reduced after Ab treatment (Shankar et al., 2007) . Interestingly, Snyder and colleagues were unable to detect a difference in the extrasynaptic staining of NMDARs in response to Ab (Snyder et al., 2005) , suggesting that the Ab-induced NMDAR endocytosis may be specific to synaptic NMDARs and may subsequently decrease downstream prosurvival signaling. More recent biochemical fractionation experiments are in agreement with this possibility; hippocampal slices treated with Ab-containing conditioned media exhibit reduced expression of PSD-95 and GluN2B in synaptic but not extrasynaptic fractions (Li et al., 2011) . Similarly, Ab decreases synaptic glutamatergic currents in autaptic hippocampal cultures (Talantova et al., 2013) . Thus, Ab appears to specifically promote the internalization of synaptic and not extrasynaptic NMDARs, altering the balance between synaptic and extrasynaptic NMDAR signaling.
While immunohistochemical and biochemical data suggest that Ab does not redistribute NMDARs from synaptic to extrasynaptic sites in a manner that enhances the quantity of extrasynaptic NMDARs (Li et al., 2011; Snyder et al., 2005) , it is well established that Ab oligomers can facilitate tonic glutamate buildup in the extracellular space, activating extrasynaptic NMDARs. D-[3H]-aspartate binding (a marker of glutamate transporters) is reduced in AD brains (Masliah et al., 1996) and a reduction in the expression of glutamate transporters is observed both in human tissue from AD patients (Chen et al., 2011) and animal models of AD (Masliah et al., 2000; Schallier et al., 2011) . Moreover, studies investigating the effect of Ab on hippocampal neurons found an enhancement of presynaptic glutamate release, an inhibition of glial glutamate uptake, and a general increase in the concentration of extracellular glutamate (Abramov et al., 2009; Danysz and Parsons, 2012) . A recent study also showed that Ab triggers ubiquitination and subsequent reduction in the surface expression of the glial glutamate transporter GLT-1, dramatically diminishing the rate at which synaptically released glutamate is cleared (Scimemi et al., 2013) . When synaptic NMDARs are preblocked with MK-801, Ab from a variety of sources, including cell culture, human brain extracts, and synthetic Ab, can still induce an NMDAR-dependent current (Li et al., 2011; Talantova et al., 2013) . As this effect can be blocked by Ro25-6981, it suggests that Ab results in an increased activation of GluN2B-containing extrasynaptic NMDARs.
In addition to reducing glutamate uptake, Ab can also contribute to extrasynaptic NMDAR activation by triggering glutamate release from glial cells. By measuring whole-cell currents from cultured microglia, Noda and colleagues demonstrated that outward currents (representing the corelease of glutamate and sodium) in response to potassium stimulation are significantly larger in cultures treated with Ab (Noda et al., 1999) . The authors also measured glutamate concentration in the conditioned media and confirmed that Ab-treated cultures respond to potassium stimulation with an enhanced release of glutamate. A more recent study (Talantova et al., 2013) employed a novel fluorescent glutamate sensor called SuperGluSnFr to measure glutamate release dynamics in cultured astrocytes with precise spatial and temporal resolution. The authors observed a rapid calcium-dependent increase in glutamate release from pure astrocyte cultures in response to oligomeric but not monomeric Ab application. Interestingly, this effect is dependent on the activation of a7 nicotinic acetylcholine receptors, consistent with previous work demonstrating that Ab directly binds these receptors (Wang et al., 2000) . Thus, in addition to reducing glutamate uptake, Ab also has a direct effect on glial glutamate release, further increasing the probability of extrasynaptic NMDAR activation.
Synaptic activity and exocytosis drives the release of Ab into the extracellular space (Cirrito et al., 2005) and synaptic versus extrasynaptic NMDAR activation can differentially influence the production and/or secretion of Ab. General NMDAR activation by bath NMDA application to cultured cortical neurons increases the production and secretion of Ab by upregulating the expression of amyloid precursor proteins (APPs) containing a Kunitz protease inhibitory domain (KPI; Lesné et al., 2005) . This KPI domain associates with and inhibits the a-secretase ADAM17 (also known as tumor necrosis factor a converting enzyme [TACE] ) and promotes b-secretase cleavage of APP into toxic Ab fragments (Lesné et al., 2005) . Interestingly, selective stimulation of extrasynaptic NMDARs after synaptic NMDAR preblock still enhances KPI-containing APPs and Ab production (Bordji et al., 2010) . On the other hand, stimulating synaptic receptors alone with bicuculline and 4-AP increases BDNF mRNA and has no effect on KPI-APP or Ab expression. In fact, synaptic NMDAR activity actually increases a-secretase-mediated nonamyloidogenic processing of APP (Hoey et al., 2009 ). This extrasynaptic NMDAR-mediated production of Ab thus creates a toxic positive feedback in which Ab promotes extrasynaptic NMDAR activity, which stimulates further Ab production and secretion. Interfering with this positive feedback may provide therapeutic benefit to AD patients.
Signaling Pathways Associated with Extrasynaptic NMDARs and AD Pathogenesis.
Many studies have identified key signaling pathways involved in the pathogenesis of AD. Given the strong evidence for enhanced extracellular glutamatergic tone in AD, it is not surprising that significant overlap exists between the signaling molecules implicated in AD and those influenced by extrasynaptic NMDAR stimulation. CREB-mediated gene expression is essential for cell survival and plasticity as well as learning and memory, and CREB phosphorylation at serine-133, which is required for its transcriptional activity, is decreased in AD (Saura and Valero, 2011; Yamamoto-Sasaki et al., 1999) , and after extrasynaptic NMDAR stimulation (Hardingham et al., 2002) . Treatments such as rolipram and forskolin that increase the cAMP signaling pathway can restore CREB phosphorylation as well as the synapse loss and LTP deficits thought to contribute to the cognitive deficit in AD (Smith et al., 2009; Vitolo et al., 2002) . Jacob translocates to the nucleus after Ab treatment (Dieterich et al., 2008) , most likely in the nonphosphorylated form, since phosphorylated Jacob is translocated after synaptic NMDAR stimulation and is associated with BDNF, CREB, and Arc signaling as well as neuroprotection (Karpova et al., 2013) . On the other hand, nonphosphorylated Jacob is translocated after extrasynaptic NMDAR stimulation and is associated with decreases in CREB activity, dendritic complexity, and synaptic density (Karpova et al., 2013) . Furthermore, the effect of Ab on Jacob translocation is completely blocked by the GluN2B-specific antagonist ifenprodil (Rö nicke et al., 2011) , demonstrating that the Ab-induced Jacob translocation is dependent upon GluN2B-containing NMDARs.
The neurotrophic factor BDNF can promote serine-133 CREB phosphorylation through CaMKIV or ERK1/2 activation; moreover, the BDNF gene is a CREB target (Tao et al., 1998) , creating a positive feedback between these two prosurvival factors. As with CREB activity levels, BDNF is decreased in the brain Phillips et al., 1991) , serum, and cerebrospinal fluid (Laske et al., 2006) of human AD patients as well as in AD mouse models (Blurton-Jones et al., 2009; Peng et al., 2009) . Notably, BDNF induction is suppressed by extrasynaptic NMDAR activity (Hardingham et al., 2002) . In a transgenic mouse model of AD, much of the cognitive deficit can be restored after stem cell implantation. Interestingly, this effect is dependent upon BDNF release from the newly implanted cells, as the effect is mimicked by recombinant BDNF and abolished by depletion of BDNF from the stem cells (Blurton-Jones et al., 2009 ). Furthermore, cognition is improved despite a lack of improvement in the Ab or tau pathology, suggesting an important role for BDNF inactivation downstream of Ab and tau in AD pathogenesis (Blurton-Jones et al., 2009) . Similarly, viral delivery of CREB-binding protein (CBP) increases BDNF expression and improves the cognitive deficits in an animal model of AD, without effect on Ab or tau pathology (Caccamo et al., 2010 ). These studies demonstrate that Ab and tau toxicity rely at least in part on downstream negative effects on CREB and BDNF signaling.
While the discussion thus far has centered on the link between Ab and extrasynaptic NMDAR signaling, it is also well established that hyperphosphorylation of the tau protein is critical to AD pathogenesis (Gong and Iqbal, 2008) . Tau phosphorylation levels are up to four times higher in AD brains (Kö pke et al., 1993) and Ab fails to induce its toxic effects in the absence of tau (Rapoport et al., 2002) . Although tau is phosphorylated at many different sites, research has pointed to a few key kinases that largely regulate its phosphorylation state in AD. Glycogen synthase kinase 3b (GSK-3b) is one particular tau kinase that is activated by Ab application (Hoshi et al., 2003) and contributes to Ab-induced tau phosphorylation and toxicity (Tackenberg et al., 2013) . Interestingly, extrasynaptic NMDAR activation exacerbates tau toxicity, and blockade of GluN2B-containing NMDARs inhibits Ab-induced GSK-3b activation, tau phosphorylation, and toxicity (Tackenberg et al., 2013) . Similarly, fluorescent tracking experiments demonstrate that the Ab-dependent impairment of axonal transport is significantly attenuated by NMDAR antagonists or by GSK-3b inhibition (Decker et al., 2010) , further supporting a link between NMDARs and GSK-3b activation. Selective synaptic NMDAR activation can inhibit GSK-3b though Akt-mediated phosphorylation at serine-9 (Soriano et al., 2006), suggesting a mechanism by which synaptic NMDAR activation may be protective in AD.
A second tau kinase highly implicated in AD development is cyclin-dependent kinase 5 (cdk5). Cdk5 activation is increased after general glutamate application and glutamate-induced toxicity can be rescued by a cdk5 inhibitor (Miao et al., 2012) . Recently, it was shown that Ab induces an extrasynaptic NMDAR-dependent increase in nitric oxide (Talantova et al., 2013) , which can activate cdk5 through nitrosylation; this process contributes to the harmful effects of Ab, including downstream transnitrosylation of dynamin-related protein 1 (Drp1) that results in mitochondrial dysfunction, bioenergetic failure, and synapse loss Qu et al., 2011) . Moreover, nitrosylated cdk5 is enhanced in AD brains (Qu et al., 2011) and thereby may also contribute to tau hyperphosphorylation. Ab can also contribute to cdk5 activation through calpaindependent cleavage of p35 to p25, while inhibition of cdk5 or calpain can reduce Ab toxicity . Thus, extrasynaptic NMDAR activation may promote tau phosphorylation through various mechanisms. Indeed, selective activation of extrasynaptic NMDARs after synaptic NMDAR preblock with MK-801 enhances tau phosphorylation in cultured hippocampal neurons (Talantova et al., 2013) .
Additional data further support the link between extrasynaptic NMDAR activity and AD pathogenesis. For example, caspase-3 (Talantova et al., 2013; Wang et al., 2004) , FoxO3a (Qin et al., 2008) , and p38MAPK (Hensley et al., 1999; Wang et al., 2004) are all associated with AD neuropathology and are also activated by increased extrasynaptic NMDAR activity (Hardingham and Bading, 2010) . Furthermore, the oxidative stress induced by Ab can be blocked by memantine (De Felice et al., 2007) , an NMDAR antagonist that shows specificity for extrasynaptic over synaptic NMDARs (Xia et al., 2010 ; but see Wroge et al., 2012) , and the impaired glutamate uptake in AD can be prevented by the vitamin E derivative Trolox (Scimemi et al., 2013) . Finally, it was recently shown that phosphorylation of the histone protein H2AX, which is a marker for DNA double strand breaks in neurons, is increased after Ab application and that this increase is dependent upon extrasynaptic NMDARs (Suberbielle et al., 2013 
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Synaptic Plasticity in AD. There has been overwhelming support for the notion that Ab oligomers from a variety of sources and of varying concentrations can severely impair NMDARdependent LTP at hippocampal CA1 and dentate gyrus synapses both in vitro and in vivo (reviewed in Danysz and Parsons, 2012) . As Ab can also increase the extracellular availability of glutamate, it follows that the LTP deficit may result from an overstimulation of extrasynaptic NMDARs, as reviewed above. Indeed, Ab-induced LTP inhibition can be prevented by GluN2B antagonists at low concentrations that did not alter plasticity in control conditions (Hu et al., 2009) or by preincubation with memantine (Rammes et al., 2011) . Similarly, Rö nicke and colleagues found that GluN2B antagonists can block the detrimental effects of Ab on not only LTP but also on basal synaptic transmission, network activity, and spine density (Rö nicke et al., 2011) . A more direct link to extrasynaptic receptors was made recently when it was demonstrated that Ab-induced LTP impairment could be ameliorated by decreasing extracellular glutamate levels (Li et al., 2011) . Notably, the LTP impairment in AD can also be prevented by inhibition of p38MAPK or calpain (Li et al., 2011) , both of which are selectively activated by extrasynaptic NMDARs.
In all, a large body of evidence supports a significant role for enhanced extrasynaptic NMDAR activity in the pathogenesis of AD. Some of the pathways and mechanisms discussed above are summarized in Figure 2 .
Huntington Disease
Evidence for an Extrasynaptic NMDAR Involvement in Huntington Disease. Huntington disease (HD) is an autosomal dominant neurodegenerative disease caused by a CAG repeat expansion in the gene encoding the huntingtin protein (Htt). This protein (mutant huntingtin [mHtt] ) results in deficits in synaptic signaling, plasticity, and eventual cell death that is particularly striking in the striatum. While the neurobiological consequences of mHtt are broad and impact many aspects of cellular function (Zuccato et al., 2010) , recent advances in the field have highlighted an important role of extrasynaptic NMDAR signaling in HD pathogenesis (Milnerwood et al., 2010; Okamoto et al., 2009 ). Many of the mechanisms and pathways related to enhanced NMDAR signaling in HD are summarized in Figure 3 and discussed in detail in the following sections.
In virtually all of the animal models available for the study of HD , an increase in NMDAR-mediated currents, particularly in striatal medium-sized spiny projection neurons (SPNs), has been observed . Moreover, it is well established that mHtt increases neuronal susceptibility to NMDA-induced toxicity (Fan and Raymond, 2007; Zeron et al., 2002; Zhang et al., 2008) . In fact, intrastriatal injections of glutamate receptor agonists were initially used as a model of HD due to their ability to recapitulate key features of the disease (Beal et al., 1986; Coyle and Schwarcz, 1976) . It is now becoming clear that the major NMDAR contributors to (1) Toxic soluble oligomers of Ab can bind directly to a7 nicotinic acetylcholine receptors to trigger calcium-dependent release of glutamate from astrocytes. This can result in increased extracellular glutamate acting on extrasynaptic NMDARs. (2) Glutamate transporter expression is decreased in AD, resulting in impaired glutamate uptake that also contributes to extrasynaptic NMDAR activation. (3) Ab itself can bind to NMDARs and has been suggested to directly activate them. Whether this occurs preferentially at synaptic or extrasynaptic sites remains to be seen. (4) Ab actions on a7 nicotinic channels can also promote synaptic NMDAR internalization by activating protein phosphatase 2B (PP2B), which dephosphorylates and activates STEP. Active STEP then dephosphorylates NMDARs at Y 1472 , resulting in synaptic NMDAR internalization, further shifting the balance toward extrasynaptic NMDAR signaling. (5) As a result of enhanced extracellular glutamate, extrasynaptic NMDARs are highly active. This gives rise to nitric oxide (NO) production, which activates cdk5 via S-nitrosylation. S-nitrosylated (SNO) cdk5 can transnitrosylate Drp1, which results in mitochondrial fragmentation. As cdk5 is a known tau kinase, it is also possible that SNO-cdk5 contributes directly to enhanced tau phosphorylation. Extrasynaptic NMDAR activity also activates GSKb, which contributes to tau hyperphosphorylation in AD. (6) Elevated extrasynaptic NMDAR activity is also associated with ERK1/2 inhibition (dephosphorylation) and the translocation of Jacob (likely in its nonphosphorylated state) to the nucleus, where it has a negative effect on CREB-mediated transcription. The transcription factor FoxO3a is also translocated to the nucleus in AD and after extrasynaptic NMDAR activity and may increase the expression of cell death genes. Extrasynaptic NMDAR activation is also linked to increased expression of KPI domain-containing APP, which facilitates b-secretase (bsec) cleavage of APP into Ab, which can then be released to the extracellular space in an activity-dependent manner. An enhancement of DNA double strand breaks (DSB) is observed in AD and is dependent upon extrasynaptic NMDAR activity. AD is also associated with increased levels of p38MAPK (p38), which may arise as a result of extrasynaptic NMDAR-induced calpain cleavage of STEP (from STEP 61 to STEP 33 ) and subsequent p38MAPK activation. See text for additional details and references. mHtt-associated toxicity are those located outside the synapse. Electrophysiological and biochemical approaches reveal an increase in extrasynaptic NMDARs in the yeast artificial chromosome (YAC) mouse model of HD with 128 CAG repeats (YAC128). Isolated NMDAR currents recorded from SPNs are larger for YAC128 mice when high stimulus intensities, or the glutamate transporter inhibitor DL-threo-b-Benzyloxyaspartic acid (TBOA), are used to promote glutamate spillover. Furthermore, the expression level of GluN2B is increased in nonsynaptic membrane fractions from YAC128 striatum and cortex (Milnerwood et al., 2010) . In primary neuronal culture, residual NMDAR current after synaptic NMDAR preblock is increased in mHttexpressing neurons Puddifoot et al., 2012) , further suggestive of enhanced extrasynaptic NMDARs in HD. GluN2B generally exhibits faster lateral diffusion than GluN2A subunits, at least in cultured neurons (Groc et al., 2006) . However, in mHtt-expressing striatal neurons, there is enhanced extrasynaptic localization of the scaffold PSD-95, which associates more strongly with GluN2B, probably resulting in greater stability of GluN2B-containing NMDARs outside the synapse (Fan et al., 2009 . Memantine, at low concentrations, abolishes the enhanced sensitivity of mHtt-expressing cultured neurons to glutamate-induced cell death (Okamoto et al., 2009) and in YAC128 mice memantine treatment improves motor performance and rescues striatal SPN loss (Milnerwood et al., 2010; Okamoto et al., 2009 ). The importance of GluN2B-containing NMDARs in HD is demonstrated by the fact that ifenprodil can mimic the effect of memantine in alleviating the enhanced susceptibility to excitotoxic insult associated with mHtt expression (Okamoto et al., 2009; Zeron et al., 2002) .
In addition to GluN2B NMDARs, recent evidence suggests that HD is associated with an upregulation of surface GluN3A-containing NMDARs as a result of mHtt-induced sequestration of the endocytic adaptor protein PACSIN1 (Marco et al., 2013) . Since GluN3A expression negatively impacts synapse formation and/or stabilization (Henson et al., 2010) , increased expression in HD can reduce the amount of prosurvival signaling occurring through synaptic NMDARs. Notably, crossing HD mice with mice lacking GluN3A receptors ameliorates many of the synaptic, neuropathological, and behavioral deficits associated with HD (Marco et al., 2013) . GluN3A overexpression is also known to increase the amount of GluN2B at extrasynaptic sites, possibly by forming a complex that includes GluN1 and GluN2B together with GluN3A that anchors relatively poorly at the postsynaptic density (Martínez-Turrillas et al., 2012) . However, it remains unclear whether the GluN3A present in HD striatal tissue forms a complex with GluN2B subunits, or whether the elevated GluN3A levels contribute to a separate, diheteromeric GluN1-GluN3A receptor population.
Studies on the mechanisms underlying NMDAR mislocalization in HD are ongoing and likely to involve alterations in posttranslational modifications including phosphorylation, (1) Enhanced synaptic STEP signaling in HD can result in NMDAR dephosphorylation at Y 1472 , promoting lateral movement of NMDARs away from synaptic sites. When outside the synapse, enhanced calpain signaling in HD increases the cleavage of the NMDAR C-terminal tail, which may effectively reduce clathrin-mediated endocytosis, thereby leaving more NMDARs at the extrasynaptic surface. (2) The largely synaptic scaffolding protein PSD-95 is elevated at extrasynaptic sites in HD and associates with GluN2B subunits. This interaction is required for the enhanced basal levels of p38MAPK (p38) in HD. There is also an increased surface expression of GluN3A-containing NMDARs due to decreased endocytosis as a result of mHtt sequestration of the endocytic adaptor PACSIN1. Whether GluN3A subunits form the same or different receptor complexes as GluN2B-containing NMDARs remains to be seen. (3) GLT-1 depalmitoylation decreases its function in HD, resulting in poor uptake of synaptically released glutamate, thereby increasing the chances of extrasynaptic NMDAR activation. (4) Enhanced extrasynaptic NMDAR activity in HD increases Rhes, which SUMOylates and disaggregates mHtt. Disaggregation of mHtt is thought to increase its toxicity by, for example, sequestering CBP and preventing its nuclear entry and support of CREB-mediated gene transcription. mHtt also acts in the nucleus to suppress PGC-1a expression by interfering with both CREB and TAF4-mediated transcription. Reduced PGC-1a can, in turn, increase extrasynaptic NMDAR currents in a toxic positive feedback cycle. Extrasynaptic NMDAR activation may also contribute more directly to CREB shutoff and decreased PGC-1a expression by an undetermined mechanism. See text for details and references. palmitoylation, and proteolytic cleavage and has been recently reviewed elsewhere . Both calpain-mediated cleavage of the GluN2B C terminus, as well as STEP-induced regulation of GluN2B phosphorylation, contribute to the change in the synaptic/extrasynaptic balance of striatal GluN2B-containing NMDAR in presymptomatic YAC128 mice . In addition, HD has been linked to deficits in palmitoylation of synaptic proteins (Young et al., 2012) , particularly through an altered association between mHtt and the palmitoyl acyltransferase DHHC17 (huntingtin interacting protein 14 [HIP14]; Huang et al., 2011; Singaraja et al., 2011) . Palmitoylation of NMDAR subunits influences their surface expression and targeting to the synapse (Hayashi et al., 2009; Mattison et al., 2012) , and DHHC17 knockout mice share similar synaptic, neuropathological and behavioral deficits with other HD mouse models (Milnerwood et al., 2013; Singaraja et al., 2011) . In light of the enhanced PSD-95/GluN2B interaction in HD, it is worth noting that palmitoylation of PSD-95 targets this scaffold to synapses (Craven et al., 1999) and that PSD-95 palmitoylation is decreased in DHHC17 knockout mice . Thus, it is of interest for future studies to determine whether altered palmitoylation of NMDARs and/or PSD-95 is responsible for receptor mislocalization in HD.
As mentioned, mHtt expression imparts a wide variety of cellular and synaptic effects and the increase in extrasynaptic NMDAR expression is just one of many potentially toxic consequences of mHtt expression. The glutamate transporter system would normally prevent excess tonic glutamate buildup and subsequent overactivation of extrasynaptic NMDARs. However, as we have seen with AD, HD is also associated with impaired glutamate uptake. In the R6/2 model of HD that expresses the N-terminal fragment of Htt with a pathological number of CAG repeats, there is an early, presymptomatic decrease in the expression of glial glutamate transporter GLT-1 mRNA in both the striatum and cortex (Lié vens et al., 2001 ). In contrast, there have been mixed reports regarding the protein expression levels of GLT-1 and other glutamate transporters, with some studies showing decreased expression in HD (Faideau et al., 2010; Lié vens et al., 2001 ) and others showing no change (Huang et al., 2010; Miller et al., 2008) . Despite the lack of consensus regarding glutamate transporter expression in HD, it is clear that glutamate uptake by these transporters is impaired beginning at presymptomatic stages of disease; this has been shown by D-aspartate binding (Lié vens et al., 2001) , microdialysis (Miller et al., 2008) , and by measurements of synaptosomal glutamate uptake (Huang et al., 2010; Lié vens et al., 2001) . Moreover, the data are in agreement across HD animal models, and decreased glutamate uptake is also observed in human HD brains (Cross et al., 1986; Hassel et al., 2008) . There is at least some regional specificity as striatal uptake impairments appear first, followed by the cortex. The cerebellum, which is largely spared in HD, is also spared from deficient glutamate uptake (Huang et al., 2010) . Interestingly, when mHtt expression is restricted to astrocytes, glutamate uptake is still diminished relative to controls, suggesting cell-autonomous effects of mHtt within astrocytes (Huang et al., 2010) . Moreover, aberrant firing of cortical afferent neurons may also contribute to glutamate abundance in the HD striatum (Cepeda et al., 2003) . The finding that increasing GLT-1 expression can improve the HD phenotype in the R6/2 mouse model suggests that targeting the uptake deficit in isolation may provide at least some therapeutic benefit to HD patients (Miller et al., 2008) .
Signaling Pathways Associated with Extrasynaptic NMDARs and HD Pathogenesis. Since the discovery of the underlying genetic cause of HD, there has been a wealth of information demonstrating transcriptional deficiencies as a result of mHtt expression (Sugars and Rubinsztein, 2003) . The Htt protein interacts with a large array of intracellular binding partners involved in many aspects of cellular function (Shirasaki et al., 2012) . Altered binding of mHtt with some of these partners probably contributes to the transcriptional deficits in HD. For example, mHtt binds CBP more strongly than does Htt, and this enhanced binding prevents CBP nuclear entry, thereby suppressing CREB/CBP-mediated transcription (Cong et al., 2005; Nucifora et al., 2001; Steffan et al., 2000) . In addition, the enhanced extrasynaptic NMDAR signaling in HD contributes to CREB shutoff; NMDA treatment after synaptic NMDAR preblock in cultured neurons decreases nuclear pCREB to a greater extent in cultures from HD mice , and low-dose memantine treatment restores pCREB in HD mouse striatum to wild-type levels (Dau et al., 2014; Milnerwood et al., 2010) . These findings offer hope that targeting extrasynaptic NMDARs may be of benefit to HD patients even in the continued presence of mHtt expression.
The increased association between extrasynaptically located GluN2B and PSD-95 in HD suggests the possibility that downstream nitric oxide signaling may play a critical role in mHttinduced toxicity (Sattler et al., 1999) . However, it was shown that while this interaction does indeed contribute to the pathogenesis of HD, it does so in a manner that is independent of nitric oxide signaling (Fan et al., 2009) . Rather, striatal neuron toxicity in HD is highly dependent on p38 MAPK signaling; p38 MAPK inhibition or disruption of the PSD-95/GluN2B interaction completely abolishes the enhanced NMDA-mediated cell death that is observed in cultured striatal neurons from YAC128 mice . In support of an extrasynaptic NMDAR involvement, memantine treatment of YAC128 mice was recently shown to restore p38 MAPK activity back to wild-type levels (Dau et al., 2014) . Extrasynaptic NMDAR stimulation also increases the expression of Rhes, a striatally enriched protein that contributes to HD pathogenesis by inducing sumoylation and disaggregation of mHtt (Okamoto et al., 2009; Subramaniam et al., 2009) . The enrichment of Rhes in the striatum has been proposed to explain the enhanced vulnerability of striatal neurons to the Htt mutation and makes Rhes an attractive target for the treatment of HD (Mealer et al., 2013) .
There is recent interest in the possibility that enhanced extrasynaptic NMDAR activity can promote further NMDAR trafficking to, and/or stabilization within, extrasynaptic sites in a potentially toxic positive feedback cycle. For example, calpain activity is increased after extrasynaptic but not synaptic NMDAR stimulation (Xu et al., 2009) and is elevated in the YAC128 model of HD at presymptomatic ages (Dau et al., 2014; Gladding et al., 2012) . These findings raise the possibility that enhanced extrasynaptic NMDAR tone in HD may promote elevated basal calpain activity. On the other hand, calpain inhibition reverses NMDAR mislocalization in HD, demonstrating that active calpain promotes extrasynaptic NMDAR expression, possibly through calcium-dependent cleavage of GluN2B subunits Gladding and Raymond, 2011) . However, this appears to be true only at early presymptomatic stages of disease progression (Dau et al., 2014) . Similarly, expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1a) is reduced by mHtt through direct associations with the promoter (Cui et al., 2006) , as well as via extrasynaptic NMDARs (Okamoto et al., 2009 ). Interestingly, siRNA-based knockdown of PGC-1a increases extrasynaptic NMDAR currents and vulnerability to excitotoxicity in cultured neurons, whereas PGC-1a overexpression has the opposite effect (Puddifoot et al., 2012) .
Synaptic Plasticity in HD. HD is associated with debilitating cognitive deficits that often appear prior to the onset of overt motor symptoms (Stout et al., 2011; Van Raamsdonk et al., 2005) . This is likely to result from underlying deficits in synaptic plasticity, which have been observed in mouse models (Milnerwood et al., 2006; Murphy et al., 2000; Usdin et al., 1999) as well as HD patients (Orth et al., 2010) . Specifically, in HD mice, impaired LTP is readily observed at the CA3-to-CA1 synapse and correlates with poor performance on hippocampal-dependent learning tasks. Much remains to be investigated with regard to the mechanisms underlying the plasticity impairment in HD.
However, there appears to be an important role for BDNF, as treatments that upregulate BDNF, or direct exogenous BDNF application, restore LTP and cognitive performance in HD mice (Lynch et al., 2007; Simmons et al., 2009 ). There is a relative lack of BDNF production in HD that is at least in part attributed to a loss of function of the nonpathogenic Htt protein (Gauthier et al., 2004; Zuccato et al., 2001) . Although it has yet to be tested, it is quite possible that extrasynaptic NMDAR activity also contributes to the BDNF reduction and/or the impairment in synaptic plasticity. As mentioned, BDNF is a downstream target of CREB, and the basal pCREB reduction in the YAC model of HD is restored by memantine treatment (Milnerwood et al., 2010) . Thus, it is of interest for future studies to determine whether increasing glutamate uptake and/or decreasing extrasynaptic NMDAR signaling can restore Hebbian plasticity and cognitive capabilities in HD. Ischemia It has long been known that ischemic events increase the extracellular concentration of glutamate to toxic levels, which appears to be mediated in large part by decreased glutamate uptake and reversed glutamate transport (Choi and Rothman, 1990; Jabaudon et al., 2000; Rossi et al., 2000) , as well as increased presynaptic vesicular release (Fleidervish et al., 2001) . Thus, in light of research over the last decade demonstrating the importance of extrasynaptic NMDARs to excitotoxic cell death, there has been recent interest in determining whether the localization of surface NMDARs can also negatively impact neuronal health after ischemic insults. Research in cell culture has shown that oxygen-glucose deprivation, conditions simulating ischemia, can activate extrasynaptic NMDARs and decrease CREB phosphorylation (Hardingham et al., 2002) and that pharmacological reversal of glutamate transport triggers cell death via extrasynaptic NMDAR activation (Gouix et al., 2009 ). Oxygen-glucose deprivation was also found to induce extrasynaptic NMDARmediated slow inward currents in hippocampal neurons that are dependent upon astrocytic calcium waves, further suggesting that glial glutamate release during energy deprivation can activate NMDARs outside the synapse. In vivo, death-associated protein kinase 1 (DAPK1) increases its association with GluN2B but not GluN2A subunits after ischemia, resulting in enhanced GluN2B phosphorylation and extrasynaptic NMDAR currents (Tu et al., 2010) . Preventing astrocytic calcium waves, selective blockade of GluN2B-containing NMDARs, genetic deletion of DAPK1, or peptide-mediated disruption of the DAPK1-GluN2B interaction were all found to significantly reduce infarct volume after ischemia Gotti et al., 1988; Tu et al., 2010) . Moreover, in rodents and nonhuman primates, disrupting signaling downstream of NMDAR activity with the Tat-NR2B9c peptide, which preferentially disrupts GluN2B interactions with postsynaptic MAGUKs including PSD-95, reduces infarct volume when administered after an ischemic event (Aarts et al., 2002; Cook et al., 2012) .
After extrasynaptic but not synaptic NMDAR activation, the expression of a calcium-activated chloride channel, Clca1, is upregulated, and overexpressing Clca1 in hippocampal neurons causes cell death (Zhang et al., 2007) . Interestingly, extrasynaptic NMDAR-dependent Clca1 expression is upregulated after oxygen-glucose deprivation, and bilateral carotid occlusion can also increase Clca1 mRNA (Wahl et al., 2009) . Additional intracellular signaling mechanisms implicated in ischemic cell death include PTEN monoubiquitination and nuclear translocation, as well as activation of calpains, p38 and JNK MAPKs, FoxO3a, and sterol regulatory element binding protein-1 (SREBP1; Dick and Bading, 2010; Koumura et al., 2008; Ning et al., 2004; Taghibiglou et al., 2009; Zhang et al., 2013; and reviewed in Lai et al., 2011) , all of which can be triggered by GluN2B and/or extrasynaptic NMDAR activation (Dick and Bading, 2010; Hardingham and Bading, 2010; Taghibiglou et al., 2009; Zhang et al., 2013) .
While the aforementioned studies point to a critical involvement of extrasynaptic NMDARs in ischemic cell death, recent findings suggest that the respective roles for synaptic and extrasynaptic NMDARs in survival and death in ischemia are far from black and white. On the one hand, selective synaptic NMDAR activation after energy deprivation can provide neuroprotection by increasing the nuclear calcium-and CREB-dependent expression of the prosurvival transcriptional repressor Atf3 (Zhang et al., 2011) . On the other hand, a recent report demonstrates that synaptic NMDARs may contribute to hypoxic cell death. Wroge and colleagues show that although hypoxiainduced cell death in cultured hippocampal neurons can be blocked by low concentrations of memantine, it is due to memantine's actions on synaptic rather than extrasynaptic NMDARs and that synaptic NMDAR activity is actually the major contributor to cell death in their model (Wroge et al., 2012) . However, it should be noted that these experiments combined hypoxic conditions with magnesium-free solutions, probably providing a level of tonic synaptic NMDAR activation that would not be observed in either physiological or pathological conditions in the human brain. In such a case, it is not overly surprising that memantine demonstrated significant synaptic NMDAR blockade. Another study that also concluded a role for synaptic NMDARs in OGD-induced excitotoxicity was similarly performed in zero-magnesium solutions (Sattler et al., 2000) . Nonetheless, these studies demonstrate the ability for synaptic NMDARs to signal to cell death under certain experimental conditions that promote their tonic activation.
Pannexin hemichannel opening has been linked to ischemic cell death by promoting large anoxic depolarizations after NMDAR and Src family kinase activation (Thompson et al., 2006; Weilinger et al., 2012) . Similarly, NMDAR activation also increases calcium influx through TRPVM7 channels that contributes to ischemic cell death (Aarts et al., 2003) . Presently, it remains unknown whether synaptic or extrasynaptic NMDARs display preferential association with pannexin hemichannels and TRPVM7 channels. In all, there is good evidence suggesting that tonic NMDAR activation after a combination of enhanced vesicular release and impaired/reversed uptake of glutamate represents a major contributor to ischemic cell death. In such a case, an appropriate therapeutic strategy would be to achieve rapid reversal of the glutamate buildup as soon as possible after an ischemic event.
Extrasynaptic NMDAR Involvement in Other Disorders of the CNS Evidence suggests that extrasynaptic NMDAR activity can also play a prominent role in the cell death associated with other CNS disorders. Excessive extracellular glutamate levels are observed after traumatic brain injury (TBI) (Baethmann et al., 1989; Katayama et al., 1990) and mechanical stretch injury to cultured cortical neurons was recently found to augment extrasynaptic GluN2B-containing NMDAR currents (Ferrario et al., 2013) . Furthermore, decreased synaptic GluN2B content is also observed after TBI, further shifting the balance from synaptic to extrasynaptic NMDAR signaling (Park et al., 2013) . Similarly, status epilepticus has long been known to induce delayed cell death and cognitive decline, and a role of extrasynaptic NMDARs in this process has been uncovered. Epileptiform activity increases astrocytic calcium, resulting in glial glutamate release and extrasynaptic GluN2B-containing NMDAR activation (Ding et al., 2007) . Electron microscopy has demonstrated an increase and decrease in GluN2B content outside and inside the synapse, respectively, after experimental epilepsy in rats, and pharmacological blockade of GluN2B-containing NMDARs is neuroprotective in this model (Frasca et al., 2011) . Moreover, as extrasynaptic NMDARs respond to glial glutamate release, it is possible that their activation is critical to the synchronized neuronal activity associated with epileptic seizures (Fellin et al., 2004; Tian et al., 2005) .
Conclusions
Substantial evidence suggests a dichotomy in NMDAR function based largely on their subcellular localization and subunit composition. This dichotomy is supported by demonstrations of an extrasynaptic, GluN2B-containing NMDAR involvement in the cell death associated with neurodegenerative diseases and acute CNS injury, including AD, HD, ischemia, TBI, and epilepsy. In each case, cell death appears to be mediated at least in part by extrasynaptic NMDAR activation after enhanced glutamate spillover, glutamate release from glia, and/or an upregulation of NMDARs at extrasynaptic sites. Some of these disorders are also associated with decreased synaptic NMDAR content or activity, further shifting the balance in favor of prodeath extrasynaptic NMDAR signaling. While acceptance of the NMDAR localization hypothesis is not universal, the bulk of data suggest that localization is a major component of a hierarchy of factors that contribute to NMDAR-induced excitotocity. Advancing our understanding of these mechanisms in disease states will help design better therapeutics to restore NMDAR balance by decreasing extracellular glutamate spillover/release and tonic NMDAR activation, selectively blocking extrasynaptic NMDARs or their downstream signaling or by enhancing cell-survival NMDAR signaling.
While it is much too simple to characterize AD as hippocampal-specific and HD as striatal-specific diseases, both of these neurodegenerative diseases do show substantial differences in neurodegeneration throughout the neuroaxis. Thus, it will be of interest for future studies to determine whether enhanced extrasynaptic NMDAR activity is associated specifically with those areas affected in these disease states. Indeed, it was recently shown that GLT-1 palmitoylation, and therefore glutamate uptake capacity, in HD is impaired in the striatum and cortex, two regions highly sensitive to the effects of mHtt, while no palmitoylation deficits were observed in the relatively resistant cerebellum (Huang et al., 2010) . Furthermore, it is unknown whether extrasynaptic NMDAR activity affects all neuronal subtypes in the same way; the large majority of work regarding the localization hypothesis has been conducted on hippocampal and, in the context of HD, striatal neurons.
The sheer diversity of NMDARs (Paoletti et al., 2013) complicates comparisons of the literature under different experimental conditions and, perhaps not surprisingly, the localization hypothesis remains a controversial topic. Nonetheless, memantine is well-tolerated and FDA approved and has shown clinical benefit in moderate-to-severe AD cases, likely through either the preferential blockade of extrasynaptic NMDARs or by preventing tonic NMDAR activity, be it synaptic or extrasynaptic. Going forward, it is well worth a coordinated effort to fully understand the NMDAR involvement in cell death and survival, as it may ultimately lead to successful treatments for several disorders of the nervous system.
